Literature DB >> 19060922

Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.

C Bach1, D Mueller, S Buhl, M P Garcia-Cuellar, R K Slany.   

Abstract

The mixed-lineage leukemia (MLL) family of histone methyltransferases has become notorious for the participation of the founding member, MLL, in fusion proteins that cause acute leukemia. Despite structural conservation, no other MLL homolog has so far been found in a similar arrangement. Here, we show that fusion proteins based on Mll2, the closest relative of MLL, are incapable of transforming hematopoietic cells. Elaborate swap experiments identified the small CxxC zinc-binding region of Mll2 and an adjacent 'post-CxxC' stretch of basic amino acids as the essential determinants for the observed difference. Gel shift experiments indicated that the combined CxxC and post-CxxC domains of MLL and Mll2 possess almost indistinguishable DNA-binding properties in vitro. Within the cellular environment, however, these motifs guided MLL and Mll2 to a largely nonoverlapping target gene repertoire, as evidenced by nuclear localization, reporter assays, and measurements of homeobox gene levels in primary cells expressing MLL and Mll2 fusion proteins. Therefore, the CxxC domain appears to be a promising target for therapies aimed at MLL fusion proteins without affecting the general function of other MLL family members.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060922     DOI: 10.1038/onc.2008.443

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

Review 1.  A double take on bivalent promoters.

Authors:  Philipp Voigt; Wee-Wei Tee; Danny Reinberg
Journal:  Genes Dev       Date:  2013-06-15       Impact factor: 11.361

Review 2.  The pathogenesis of mixed-lineage leukemia.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

3.  Selective targeting of histone methylation.

Authors:  Abul B M M K Islam; William F Richter; Nuria Lopez-Bigas; Elizaveta V Benevolenskaya
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

Review 4.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

Review 5.  Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.

Authors:  Rajesh C Rao; Yali Dou
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

6.  Acute dietary zinc deficiency before conception compromises oocyte epigenetic programming and disrupts embryonic development.

Authors:  X Tian; F J Diaz
Journal:  Dev Biol       Date:  2013-01-21       Impact factor: 3.582

7.  Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.

Authors:  Xinghui Zhao; Aili Chen; Xiaomei Yan; Yue Zhang; Fuhong He; Yoshihiro Hayashi; Yunzhu Dong; Yalan Rao; Bo Li; Rajeana M Conway; Alba Maiques-Diaz; Shannon E Elf; Nuomin Huang; Johannes Zuber; Zhijian Xiao; William Tse; Daniel G Tenen; Qianfei Wang; Wei Chen; James C Mulloy; Stephen D Nimer; Gang Huang
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

8.  Proteomic approaches for cancer epigenetics research.

Authors:  Dylan M Marchione; Benjamin A Garcia; John Wojcik
Journal:  Expert Rev Proteomics       Date:  2018-11-27       Impact factor: 3.940

9.  Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.

Authors:  Tomasz Cierpicki; Laurie E Risner; Jolanta Grembecka; Stephen M Lukasik; Relja Popovic; Monika Omonkowska; David D Shultis; Nancy J Zeleznik-Le; John H Bushweller
Journal:  Nat Struct Mol Biol       Date:  2009-12-13       Impact factor: 15.369

10.  Developmentally induced Mll1 loss reveals defects in postnatal haematopoiesis.

Authors:  T Gan; C D Jude; K Zaffuto; P Ernst
Journal:  Leukemia       Date:  2010-08-19       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.